269 related articles for article (PubMed ID: 18958334)
1. [Immune tolerance therapy for inhibitors in haemophilia A].
Oldenburg J
Hamostaseologie; 2008 Oct; 28 Suppl 1():S23-5. PubMed ID: 18958334
[TBL] [Abstract][Full Text] [Related]
2. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
3. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
4. The role of VWF for the success of immune tolerance induction.
Kreuz W
Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
[TBL] [Abstract][Full Text] [Related]
5. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
DiMichele D; Kroner B;
Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
[TBL] [Abstract][Full Text] [Related]
6. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
7. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
8. [Congenital coagulopathies and coagulation factor inhibitors].
Oldenburg J; Barthels M
Hamostaseologie; 2008 Dec; 28(5):335-47. PubMed ID: 19132164
[TBL] [Abstract][Full Text] [Related]
9. [A life-threatening cardiomyopathy following port-a-cath infection under immune tolerance therapy].
Wiegand G; Rauch R; Girisch M; Hofbeck M
Hamostaseologie; 2007 Sep; 27(4):290-2. PubMed ID: 17938769
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
11. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
Thom K; Male C; Falger J; Pabinger I
Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
[TBL] [Abstract][Full Text] [Related]
13. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
Smith MP; Spence KJ; Waters EL; Beresford-Webb R; Mitchell MJ; Cuttler J; Alhaq A; Brown SA; Savidge GF
Thromb Haemost; 1999 Jan; 81(1):35-8. PubMed ID: 9974371
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of high responding inhibitors in severe haemophilia A.
Moschovi M; Aronis S; Trimis G; Platokouki H; Salavoura K; Tzortzatou-Stathopoulou F
Haemophilia; 2006 Jan; 12(1):95-9. PubMed ID: 16409183
[TBL] [Abstract][Full Text] [Related]
15. Application of current knowledge to the management of bleeding events during immune tolerance induction.
Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
[TBL] [Abstract][Full Text] [Related]
16. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
Dimichele D
Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to factor VIII in hemophilia A patients.
Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
[TBL] [Abstract][Full Text] [Related]
19. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies.
Brackmann HH; Lenk H; Scharrer I; Auerswald G; Kreuz W
Haemophilia; 1999 May; 5(3):203-6. PubMed ID: 10444288
[TBL] [Abstract][Full Text] [Related]
20. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
